Want this question answered?
what is the difference between in bone marrow and FISH test in chronic myloid leukemias
CML stands for Chronic Myeloid Leukemia, a type of cancer that affects the blood and bone marrow. It is characterized by the abnormal growth of white blood cells in the body.
myelogenous affects the bone marrow. while lymphocytic affects the lymph tissue. so there is two different patterns so be careful with terms being used. so bone marrow gets affected in myelogenous means Chronic myelogenous ( myelocytic) leukemia , in short abbreviation it is called ( CML).
CML represents the Roman numeral for 950. Roman numerals are a numeric system in which letters are used to represent numbers. In this case, C refers to 100 and M represents 1000, so the combination CML represents 950.
CML a special case of SML. While CML represents Return potential and risk involved in all financial asset across the Capital market, SML is the linear relationship between the expected return of security and its systematic risk, the expected return comparing a risk-free return plus a risk premium.
Chronic Myelogenous Leukemia a cancer that spawns within the bone marrow, contains three stages once it has begun; chronic, accelerated, and blast crisis. The chronic phase could last up to months or years with very subtle signs hardly ever noticed. During the accelerated phase where leukemia cells increase in growth speed, the victim may experience bone aches, non-infecting fever, and a swollen spleen. If the CML is not treated at this point, the victim enters the blast crisis phase, where several serious problems occur due to bone marrow failure. Symptoms during the blast crisis include: bleeding, infection, bruising, excessive sweating (and night sweating), fatigue, fever, pressure under lower left ribs, occasional rash and weakness.
The numeric value of the Roman numeral CML is 950.
Chronic Myeloid Leukaemia (CML) is a type of white blood cell cancer. It is diagnosed and monitored using a number of specialised blood tests, some specifically looking for levels of abnormal cell DNA. CML occurs when damaged cells within a person's bone marrow (where white blood cells are manufactured) begin to produce an abnormal enzyme (production chemical) that disorders the process of making white blood cells. The DNA defect is commonly known as the Philadelphia Chromosome (because that's where it was discovered). The abnormal enzyme this DNA produces causes highly immature and irregular white blood cells to be produced and released into the blood stream. It is this abnormal enzyme that is the target of most current drug therapies. Almost all patients diagnosed with CML will be treated with a drug called Gleevec (also known as imatinib, from a class of drugs called tyrosine kinase inhibitors, or TKIs). This drug prevents the enzyme from working. It has been prescribed widely for around 7 years. The majority of patients on it do very well, and because it acts specifically on the enzyme involved (unlike chemotherapy) there are few if any side effects in most people. Most patients' blood tests return to normal after a few years on the drug... The issue is whether patients with 'normal' blood work should stay on the drug or come off it. Because it is a relatively new drug we currently do not know what the potential LONG TERM effects there might be of staying on it. We do not know whether the drug would be harmful to women who are pregnant or breast-feeding, as there is no data on this. We also have no reliable evidence to suggest that coming OFF the drug is beneficial: in some patients, their CML returns once off Gleevec, and in others it does not. This is a choice that patients must make. In patients who cannot tolerate imatinib, another TKI may be tried. If this fails, then a bone marrow transplant (BMT) may be tried. This is NOT the same as a solid organ transplant (such as a kidney, where most biological family members would be suitable). Bone marrow suitable for transplant may not be found in any family member and may have to come from an unknown donor. A BMT is extremely risky (1 in 5 patients will die during, or shortly after, the procedure). Around 2 in 3 patients will be fully cured of CML forever, but this does potentially come at a cost. The long-term disabilities from BMTs CAN include permanent painful skin inflammation or life-long diarrhoea. Treatment for CML needs to be the result of joint discussions between patients, the families and expert doctors (usually haematologists).
2011Improved Answer:-CML = 950
CML means chronic myelogenous leukemia.
CML = CAL for the entire market, assuming everyone has the same mean variance expectations ( E(R), variances, correlations). CAL is just the CML for individual investors. CAL and CML both combine the risk free asset with the optimal portfolio, only with CML that optimal portfolio is the market portfolio (tangency point of CML).
CML which is a shortened version of DCCCCL